EICHOR
● Terminated
A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Condition: ALSP · Sponsor: Vigil Neuroscience, Inc.
About this study
This is a multicenter, open-label study to assess the safety and tolerability of iluzanebart (also referred to as VGL101) in subjects with documentation of a gene mutation in the CSF1R gene for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and to evaluate the effects of iluzanebart on imaging and biomarkers of disease progression in subjects with ALSP. Participants will receive infusions of iluzanebart approximately every 4 weeks for 1 year. The study includes a 52-week, open-label Core Study, followed by a Long-Term Extension (LTE), which provides subjects who complete the original 52-week study (Core Study) with the option to continue treatment for up to an additional 2 years.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (10)
| Investigative Site 3 | San Francisco, California, United States | — |
| Investigative Site 2 | Englewood, Colorado, United States | — |
| Investigative Site 1 | Jacksonville, Florida, United States | — |
| Investigative Site 5 | Boston, Massachusetts, United States | — |
| Investigative Site 6 | Philadelphia, Pennsylvania, United States | — |
| Investigative Site 10 | Paris, France | — |
| Investigative Site 7 | Leipzig, Germany | — |
| Investigative Site 9 | Tübingen, Germany | — |
| Investigative Site 8 | Amsterdam, Netherlands | — |
| Investigative Site 4 | London, United Kingdom | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05677659